Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

For the full year, Gilead now expects earnings per-share between 5 cents to 25 cents, compared with its prior view of zero cents to 30 cents. On an adjusted basis, the company expects earnings per ...